Even With Changes, NCI Always Moving Forward

Posted by Dusty Weaver on October 4th, 2005

The Director’s Update in the October 4, 2005 edition of the NCI Cancer Bulletin highlights some of the leadership changes at the National Cancer Institute (NCI) and how these changes will help NCI maintain its forward progress toward the 2015 goal to eliminate the suffering and death due to cancer by the year 2015.

NCI Director Dr. Andrew von Eschenbach started the article by stating:

>Last week brought with it an important change at the National Cancer Institute (NCI), with my appointment as interim commissioner of the Food and Drug Administration (FDA) by President Bush. And as I said at the time, I will maintain my position as NCI director and my ultimate commitment to the 2015 goal.

>To ensure that the many ambitious initiatives and programs we have launched to reach that goal continue to progress, Department of Health and Human Services Secretary Mike Leavitt has asked Dr. John Niederhuber, who recently came to NCI as deputy director for translational and clinical sciences, to serve as the NCI chief operating officer to handle much of the institute’s day-to-day management.

Dr. von Eschenbach closed his remarks by saying:

>While their missions may differ somewhat, NCI and FDA, along with the other government health agencies, share a common goal of improving public health. I am committed to leading FDA through this time of transition and fulfilling my responsibilities to NCI.

>Change is never easy, but with good people and a dedication to success, I have no doubt we can come through it for the better.

Read Dr. von Eschenbach’s article in the October 4, 2004 edition of NCI Cancer Bulletin.

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions.

C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond where appropriate.

For the best response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Donate

Support C3 and the Lisa Fund for Research

Donate to C3

Donate to The Lisa Fund

Learn more about the Lisa Fund

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe